Reviewer’s report

Title: Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Version: 2 Date: 28 August 2014

Reviewer: Joanne Edwards

Reviewer’s report:

This manuscript aimed to address if the if multi-kinase inhibitors: axitinib (VEGFR inhibitor) and crizotinib (c-MET inhibitor) could be used to inhibit bone loss in a murine model of prostate cancer. I felt that the manuscript was well wrote and the data displayed in an appropriate manner. So I have not major compulsory revisions to suggest.

However I think in order to enhance the manuscript I suggest the following as discretionary revisions

1. the authors should display the PSA levels in the mouse following castration, this in combination with the tumour growth would conclusively demonstrate that the tumours were castrate resistant.

2. IHC images of the AR in addition to the western blots as cellular location of the receptor is also important

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests